Dublin, May 07, 2026 (GLOBE NEWSWIRE) — The “Albuterol Sulfate Metered Dose Inhalers Market Report 2026” has been added to ResearchAndMarkets.com’s offering.
The albuterol sulfate metered dose inhalers market is experiencing robust growth and is projected to reach $5.57 billion by 2026, at a CAGR of 8.1%. This growth is driven by factors such as the phase-out of CFC inhalers, increasing asthma prevalence, and a rising demand for portable respiratory care devices that comply with regulatory standards.
Looking ahead, the market is anticipated to expand further, reaching $7.61 billion by 2030, maintaining a steady 8.1% CAGR. Key drivers for this forecast include the development of eco-friendly inhalers, growth in chronic respiratory diseases, and a shift to patient-centric device designs. Strategies to increase patient adherence and the widespread adoption of generic inhalers are significant trends in this period.
The rising prevalence of respiratory diseases like asthma, COPD, pneumonia, and bronchitis is a crucial factor propelling the market. These conditions, exacerbated by air pollution, lead to respiratory distress. Albuterol sulfate metered-dose inhalers provide relief by relaxing muscles around the airways, improving airflow, and reducing symptoms such as wheezing and coughing. In June 2025, World Health Organization data revealed that 81.7 million individuals globally live with chronic respiratory diseases, with 6.8 million new diagnoses annually.
Industry leaders are prioritizing advanced offerings, including generic inhalers, to boost accessibility for patients with chronic respiratory conditions. For instance, in May 2024, Amphastar Pharmaceuticals gained FDA approval for its Albuterol Sulfate inhalation aerosol, aimed at managing bronchospasm in children aged four and older. This inhaler provides rapid symptom relief, especially in asthma cases.
Innovation in eco-friendly inhalation solutions is advancing through strategic partnerships, such as the May 2024 collaboration between Bespak and DevPro. This alliance aims to utilize HFO-1234ze propellant, reducing global warming potential in respiratory devices, and fostering sustainable product development.
Prominent market players include Teva Pharmaceutical Industries, Sandoz, Cipla, Lupin, and Zydus Pharmaceuticals. In 2025, North America led the market, while the Asia-Pacific region is projected to grow the fastest by 2030. The industry spans regions including Asia-Pacific, Europe, North America, South America, and Africa, covering key markets like the USA, China, India, and Brazil.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 250 |
| Forecast Period | 2026 – 2030 |
| Estimated Market Value (USD) in 2026 | $5.57 Billion |
| Forecasted Market Value (USD) by 2030 | $7.61 Billion |
| Compound Annual Growth Rate | 8.1% |
| Regions Covered | Global |
Major Trends
- Shift Toward Hydrofluoroalkane-Based Inhalers
- Rising Use of Portable Respiratory Devices
- Expansion of Breath-Activated Inhalers
- Growth of Generic Metered Dose Inhalers
- Increased Focus on Patient Adherence
Companies Featured
- Teva Pharmaceutical Industries Ltd.
- Sandoz Group AG
- Cipla Limited
- Lupin Limited
- Zydus Pharmaceuticals Inc.
- Viatris Inc.
- Mylan N.V.
- Amneal Pharmaceuticals Inc.
- Perrigo Company plc
- Prasco Laboratories
- Sun Pharmaceutical Industries Ltd.
- Aurobindo Pharma Limited
- Dr. Reddy’s Laboratories Ltd.
- Glenmark Pharmaceuticals Limited
- Hikma Pharmaceuticals PLC
- Apotex Inc.
- Accord Healthcare Limited
- Intas Pharmaceuticals Ltd.
- Chiesi Farmaceutici S.p.A.
- Nephron Pharmaceuticals Corporation
For more information about this report visit https://www.researchandmarkets.com/r/dtxkhg
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world’s leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
- Albuterol Sulfate Metered Dose Inhalers Market
